NEW YORK – Following the announcement on Tuesday morning that Thermo Fisher Scientific plans to acquire Qiagen for approximately $11.5 billion in cash, Thermo Fisher executives provided further details on the rationale for the deal, which they expect to close in the first half of 2021, and fielded questions about potential obstacles.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.